Insufficient scRNA-seq data for expression of FBXO10 at single-cell level.
Name | Number of supported studies | Average coverage | |
---|---|---|---|
brain | 3 studies | 33% ± 14% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
thymus | 100% | 1232.28 | 653 / 653 | 100% | 4.96 | 603 / 605 |
prostate | 100% | 867.84 | 244 / 245 | 100% | 4.11 | 500 / 502 |
brain | 99% | 1082.52 | 2607 / 2642 | 100% | 8.72 | 705 / 705 |
breast | 100% | 657.74 | 459 / 459 | 97% | 3.04 | 1087 / 1118 |
adrenal gland | 100% | 1766.97 | 258 / 258 | 97% | 10.45 | 223 / 230 |
kidney | 100% | 807.69 | 89 / 89 | 95% | 2.47 | 857 / 901 |
uterus | 100% | 984.00 | 170 / 170 | 95% | 3.87 | 436 / 459 |
skin | 96% | 620.05 | 1745 / 1809 | 99% | 3.90 | 465 / 472 |
pancreas | 100% | 919.35 | 327 / 328 | 93% | 2.86 | 166 / 178 |
liver | 95% | 447.79 | 215 / 226 | 95% | 2.73 | 385 / 406 |
lung | 97% | 630.83 | 562 / 578 | 91% | 2.38 | 1055 / 1155 |
bladder | 100% | 740.90 | 21 / 21 | 86% | 2.41 | 435 / 504 |
esophagus | 100% | 809.66 | 1439 / 1445 | 85% | 1.76 | 155 / 183 |
intestine | 100% | 1429.76 | 964 / 966 | 84% | 2.03 | 445 / 527 |
stomach | 98% | 661.08 | 351 / 359 | 86% | 1.78 | 247 / 286 |
ovary | 99% | 630.06 | 179 / 180 | 85% | 1.88 | 364 / 430 |
lymph node | 0% | 0 | 0 / 0 | 100% | 12.76 | 29 / 29 |
muscle | 100% | 4031.04 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 2418.54 | 241 / 241 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 100% | 2.24 | 1 / 1 |
adipose | 100% | 680.64 | 1202 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 98% | 529.51 | 1314 / 1335 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 98% | 3.28 | 78 / 80 |
tonsil | 0% | 0 | 0 / 0 | 93% | 2.29 | 42 / 45 |
heart | 93% | 546.70 | 797 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 46% | 453.46 | 426 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0006915 | Biological process | apoptotic process |
GO_0016567 | Biological process | protein ubiquitination |
GO_0006511 | Biological process | ubiquitin-dependent protein catabolic process |
GO_0042981 | Biological process | regulation of apoptotic process |
GO_0000151 | Cellular component | ubiquitin ligase complex |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_0004842 | Molecular function | ubiquitin-protein transferase activity |
GO_0005515 | Molecular function | protein binding |
Gene name | FBXO10 |
Protein name | F-box protein 10 F-box only protein 10 |
Synonyms | PRMT11 FBX10 |
Description | FUNCTION: Substrate-recognition component of the SCF (SKP1-CUL1-F-box protein)-type E3 ubiquitin ligase complex. Mediates the ubiquitination and degradation of BCL2, an antiapoptotic protein, thereby playing a role in apoptosis by controlling the stability of BCL2. Targets also the receptor for advanced glycation end products RAGE for ubiquitination and subsequent lysosomal degradation . Directly controls HGAL/GCSAM ubiquitination and degradation and thereby decreases BCR signaling . . |
Accessions | J3KN78 F5GXN9 ENST00000432825.7 [Q9UK96-1] ENST00000541607.1 ENST00000276960.7 Q9UK96 |